Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In
  • Log Out

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
  • Log Out
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
Research ArticleArticle

Treatment of Refractory Takayasu Arteritis with Tocilizumab: 7 Italian Patients from a Single Referral Center

Enrico Tombetti, Stefano Franchini, Maurizio Papa, Maria Grazia Sabbadini and Elena Baldissera
The Journal of Rheumatology December 2013, 40 (12) 2047-2051; DOI: https://doi.org/10.3899/jrheum.130536
Enrico Tombetti
From the Unit of Internal Medicine and Immunology, and the Unit of Radiology, San Raffaele University Hospital, Milan, Italy.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: tombetti.enrico@hsr.it
Stefano Franchini
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maurizio Papa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maria Grazia Sabbadini
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elena Baldissera
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
  • eLetters
PreviousNext
Loading

Abstract

Objective. The aim of our study was to evaluate the safety and the efficacy of tocilizumab (TCZ) for refractory Takayasu arteritis (TA).

Methods. We retrospectively assessed the outcome of blocking interleukin (IL)-6 with TCZ in 7 consecutive patients with refractory TA using a combination of clinical and imaging assessment.

Results. During a median followup visit at 14 months, 4 patients taking TCZ [including 2 nonresponders to tumor necrosis factor (TNF) inhibitors] achieved clinical response, suggesting a nonredundant role for IL-6 in TA. Inflammatory markers normalized in all patients treated with TCZ. However, vascular progression occurred in 4 patients, suggesting the involvement of other inflammatory pathways and confirming the limitations of erythrocyte sedimentation rate and C-reactive protein for disease activity assessment while taking TCZ. Three patients experienced adverse events and 2 suspended TCZ.

Conclusion. TCZ may be effective in a subset of patients with refractory TA, even in cases of unresponsiveness to TNF inhibitors. Inflammatory markers are not valid markers of TA activity on TCZ. Further studies are needed to confirm these preliminary observations.

Key Indexing Terms:
  • TAKAYASU ARTERITIS
  • TOCILIZUMAB
  • INTERLEUKIN 6
  • VASCULITIS

Takayasu arteritis (TA) is a rare, idiopathic, chronic-relapsing inflammatory disease typically affecting young women, with considerable morbidity and mortality1,2. Patchy granulomatous panarteritis of the aorta and its major branches is typical of TA and may result in local pain, stenosis, occlusion, and aneurysm formation1. Systemic inflammatory reaction with constitutional symptoms and acute-phase response often accompany active disease1. Activated dendritic cells, T cells, B cells, macrophages, and multinucleated giant cells infiltrate vascular lesions1,3. Interleukin 6 (IL-6), a pivotal pleiotropic inflammatory cytokine with both local and systemic effects4, is strongly expressed in TA aortic tissue, and serum IL-6 levels are elevated in TA, particularly during active phases5,6,7.

The first goal of TA therapy is preventing the progression of vascular lesions. Medical therapy is the cornerstone of TA, although controlled clinical trials are lacking because of the rarity of TA1; some cases warrant revascularization procedures2,8. Medical therapy is based on corticosteroids, but most patients require steroid-sparing immunosuppressive agents1. Nonetheless, many patients with TA are refractory to combined steroids and immunosuppressive agents2,8,9,10.

Previous observations suggest that tocilizumab (TCZ), a humanized anti-IL-6 receptor antibody, may be an option in this setting11,12,13,14,15,16. However, a recent report describes a patient with TA treated with TCZ who experienced radiological vascular progression despite good clinical response, normalization of symptoms of active disease and inflammatory markers14.

The aim of our study was to evaluate the safety and the efficacy of TCZ for refractory TA.

MATERIALS AND METHODS

We retrospectively reviewed the treatment of the 62 patients with TA followed at our center between 2004 and 2012: 9 were treated with steroids only and 31 with both steroids and immunosuppressive agents. We proposed a biological therapy only to refractory patients [i.e., failing to obtain or maintain quiescent disease with prednisone (PD) ≤ 7.5 mg/day and at least 1 immunosuppressive drug]: 22 patients with TA received tumor necrosis factor (TNF) inhibitors and 7 received TCZ (8 mg/kg monthly). All of the patients taking TCZ met the American College Rheumatology classification criteria of TA and were entered in our study. Screening for latent tuberculosis was performed according to local guidelines.

All of the patients gave informed consent to treatment and study participation.

Patients with TA treated with TCZ underwent bimonthly assessment where symptoms, physical examination, biochemistry, and treatment changes were recorded. All patients underwent a thorough imaging evaluation with both magnetic resonance angiography (MRA) and vascular ultrasonography (US) at baseline and at the end of followup. Imaging was also repeated yearly or when disease flared (whenever possible with both MRA and US). US evaluations assessed carotid, subclavian, abdominal, and femoral areas, while MRI was focused on thoracoabdominal or cervicothoracic regions according to disease involvement. Followup ended at the suspension of TCZ, or at the time of the last visit for patients still on TCZ.

Study endpoints were efficacy and safety of TCZ in TA. TCZ efficacy was evaluated according to (1) satisfaction of response criteria and reduction of disease activity, as defined by acute-phase reactants and the US National Institutes of Health (NIH) criteria9; (2) capability of PD tapering in the absence of relapse; (3) radiological vascular evolution; and (4) need of revascularization procedures.

We defined complete response as the absence of imaging progression and of features of active disease17 while taking a PD daily dose of ≤ 7.5 mg for at least 6 months; partial response occurred if clinical improvement allowed a daily reduction of steroid by at least 50%17. Relapsing disease was defined as the loss of complete response, as defined above17.

For each patient we analyzed the course of every vascular lesion along with the serial imaging studies performed during followup. Lesions were classified as thickening (i.e., wall thickness > 1 mm), stenoses (i.e., diameter reduction > 50%), occlusions (diameter reduction > 99%), and ectasias/aneurysms. Lesions were classified as worsened during followup if the patient needed revascularization procedures or if imaging documented an increase of wall thickness or a worsening stenosis.

Statistics

Given the small size of our sample, scalar variables were evaluated using a non-normal distribution and were summarized using medians and interquartile ranges (IQR). Wilcoxon test was used for comparison between these variables.

RESULTS

Patient characteristics

Seven female patients with TA treated with TCZ were included in our study. Their median age at TA diagnosis was 24 years (IQR 23–30). Prior to TCZ, the median duration of illness was 66 months (IQR 17–82), and the median number of immunosuppressive agents (other than prednisone) was 4 (IQR 2–6; Tables 1 and 2). Other agents that patients had previously received included methotrexate (all patients), azathioprine (n = 4), cyclosporine (n = 3), cyclophosphamide (n = 2), mycophenolate mofetil (n = 2), and sirolimus (n = 2). Four patients had also been previously treated with biologic agents: infliximab (all patients), adalimumab (n = 3), and anakinra and rituximab (n = 1). At baseline, all patients had active disease according to the NIH criteria. The median followup on TCZ was 14 months (IQR 10–33). During followup, all patients received concurrent immunosuppressive therapy (1 patient changed immunosuppressive regime; data available from the authors).

View this table:
  • View inline
  • View popup
Table 1.

Patient characteristics.

View this table:
  • View inline
  • View popup
Table 2.

Laboratory variables and average prednisone daily dose (PD) at the beginning and at the end of followup (median values and IQR of 7 patients).

Efficacy evaluation

Complete response was achieved in 3 patients (without subsequent relapse) and 1 achieved partial response. Three patients satisfied the disease activity criteria at the end of followup and suspended TCZ for suboptimal disease control. Inflammatory markers normalized in all patients: median erythrocyte sedimentation rate (ESR) reduced from 34 mm/h (IQR 31–40) to 4.0 mm/h (IQR 2.0–15; p = 0.028); median C-reactive protein (CRP) declined from 13 mg/l (IQR 12–14) to 2.0 mg/l (IQR 1.0–6.0; p = 0.043; Table 2). During followup, PD dose showed a consistent, although nonsignificant, reduction; platelet count and acute phase signs on serum protein electrophoresis, which are regulated by IL-6, abated (Table 2).

At imaging evaluation, 3 patients (the ones that achieved complete response) showed improvement or stabilization of all vascular lesions without any disease progression (Table 1 and Figure 1). Two other subjects showed a single worsening lesion, and the remaining 2 developed at least 1 new lesion. For each patient, a median value of 30% of all vascular lesions improved during followup, 50% remained stable, and 10% worsened or appeared. No revascularization procedures were needed during followup.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Magnetic resonance imaging followup in 2 patients. Case A: Radiological improvement with thinning (and loss of enhancement) of left carotid arterial wall (arrowheads; A1, October 2008; A2, January 2012). Case B: Radiologic new disease onset in right carotid artery with enhanced vessel wall thickening (arrows; B1, March 2009; B2, February 2011). L: lumen; W: vessel wall.

Adverse outcomes

During followup 3 patients experienced adverse reactions: 2 had recurrent respiratory infections (1 of them had recurrent pneumonia and suspended TCZ), another subject experienced a severe maculopapular rash that subsided after TCZ suspension. Transaminase levels increased during followup (Table 2), without cases of relevant liver toxicity.

DISCUSSION

To our knowledge, only 12 adult patients with TA and treated with TCZ have been reported in the literature. We describe the first cohort consisting exclusively of patients with TA taking TCZ with regular morphological imaging followup. Four of 7 patients (including 2 nonresponders to TNF inhibitors) significantly improved, confirming preliminary observations of possible TCZ efficacy for refractory TA11,12,13,14,15,16.

Our results indicate a dichotomy between the action of TCZ on the levels of liver-borne acute-phase reactants and its ability to induce and maintain clinical remission. This was not documented in all patients; 3 patients suspended TCZ for suboptimal disease control and 1 patient who had partial response underwent radiological vascular progression, although confined to a single vascular site (Table 1). The selection of a cohort with a high number of previously unsuccessful agents and long disease duration (potentially with a particularly refractory disease) could partially contribute to limit the efficacy of the treatment. Moreover, the imaging modality we have relied on has a very high sensitivity in detecting morphological vascular progression and could further justify the higher rates of imaging progression compared with previous reports11,12,13,15,16.

Vascular histological inflammation or even imaging progression, despite clinically silent TA, is well known10,18 and has frequently been reported for patients on TCZ14,15,19. All our vascular-worsening patients needed imaging data to satisfy NIH activity criteria and showed progression without elevation of inflammatory markers.

These observations suggest that acute-phase reactants could not be valid biomarkers of disease activity during TCZ therapy and cannot be used to determine therapeutic changes. Consequently, disease activity indices including acute-phase reactants, such as NIH criteria, may be less accurate when applied to these patients. Therefore, we suggest that thorough morphological imaging be mandatory for the followup of these patients and for therapeutic decisions.

Silent vascular progression might depend on (1) local smoldering vessel inflammation quantitatively insufficient to induce a systemic reaction, or (2) local vessel inflammation recruiting pathways independent of IL-6. The 2 hypotheses are not mutually exclusive and noninflammatory factors could also play a role. Locally produced inflammatory proteins such as pentraxin-3 (a long pentraxin produced directly within the sites of arterial inflammation), whose production is not directly elicited by IL-6, have been shown to better detect TA activity than ESR and CRP20.

Our study is a pilot study and carries major limitations. It is retrospective, uncontrolled, and it analyzes a very small cohort of refractory TA patients that have, in general, failed to respond to several other treatments. Another limitation is the radiological focus on vascular morphology without concurrent functional analysis with positron emission tomography.

Our study suggests that TCZ may be effective in a subset of refractory patients with TA, even in cases unresponsive to TNF inhibitors. However, 4 of the 7 patients experienced imaging progression, and only 2 subjects remained on TCZ at the 2-year followup. Further studies are needed to confirm these preliminary observations, with larger, randomized, and multicentric trials. ESR, CRP, and other acute-phase reactants abated in all patients treated with TCZ, suggesting a nonredundant role for IL-6, but they are not valid markers of TA activity on TCZ. Hence, rigorous morphological imaging assessment should be warranted in these patients.

Acknowledgment

We thank Professor Angelo Manfredi for his counseling on manuscript writing.

  • Accepted for publication August 13, 2013.

REFERENCES

  1. 1.↵
    1. Mason JC
    . Takayasu arteritis—advances in diagnosis and management. Nat Rev Rheumatol 2010;6:406–15.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Maksimowicz-McKinnon K,
    2. Hoffman GS
    . Takayasu arteritis: what is the long-term prognosis? Rheum Dis Clin North Am 2007;33:777–86,vi.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Arnaud L,
    2. Haroche J,
    3. Mathian A,
    4. Gorochov G,
    5. Amoura Z
    . Pathogenesis of Takayasu’s arteritis: a 2011 update. Autoimmun Rev 2011;11:61–7.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Murakami M,
    2. Nishimoto N
    . The value of blocking IL-6 outside of rheumatoid arthritis: current perspective. Curr Opin Rheumatol 2011;23:273–7.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Park MC,
    2. Lee SW,
    3. Park YB,
    4. Lee SK
    . Serum cytokine profiles and their correlations with disease activity in Takayasu’s arteritis. Rheumatology 2006;45:545–8.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Noris M,
    2. Daina E,
    3. Gamba S,
    4. Bonazzola S,
    5. Remuzzi G
    . Interleukin-6 and RANTES in Takayasu arteritis: a guide for therapeutic decisions? Circulation 1999;100:55–60.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Seko Y,
    2. Sato O,
    3. Takagi A,
    4. Tada Y,
    5. Matsuo H,
    6. Yagita H,
    7. et al.
    Restricted usage of T-cell receptor Valpha-Vbeta genes in infiltrating cells in aortic tissue of patients with Takayasu’s arteritis. Circulation 1996;93:1788–90.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Maksimowicz-McKinnon K,
    2. Clark TM,
    3. Hoffman GS
    . Limitations of therapy and a guarded prognosis in an American cohort of Takayasu arteritis patients. Arthritis Rheum 2007;56:1000–9.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Kerr GS,
    2. Hallahan CW,
    3. Giordano J,
    4. Leavitt RY,
    5. Fauci AS,
    6. Rottem M,
    7. et al.
    Takayasu arteritis. Ann Intern Med 1994;120:919–29.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Freitas DS,
    2. Camargo CZ,
    3. Mariz HA,
    4. Arraes AE,
    5. de Souza AW
    . Takayasu arteritis: assessment of response to medical therapy based on clinical activity criteria and imaging techniques. Rheumatol Int 2012;32:703–9.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Nishimoto N,
    2. Nakahara H,
    3. Yoshio-Hoshino N,
    4. Mima T
    . Successful treatment of a patient with Takayasu arteritis using a humanized anti-interleukin-6 receptor antibody. Arthritis Rheum 2008;58:1197–200.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Seitz M,
    2. Reichenbach S,
    3. Bonel HM,
    4. Adler S,
    5. Wermelinger F,
    6. Villiger PM
    . Rapid induction of remission in large vessel vasculitis by IL-6 blockade. A case series. Swiss Med Wkly 2011;141:w13156.
    OpenUrlPubMed
  13. 13.↵
    1. Salvarani C,
    2. Magnani L,
    3. Catanoso MG,
    4. Pipitone N,
    5. Versari A,
    6. Dardani L,
    7. et al.
    Rescue treatment with tocilizumab for Takayasu arteritis resistant to TNF-alpha blockers. Clin Exp Rheumatol 2012;1 Suppl 70:S90–3.
    OpenUrl
  14. 14.↵
    1. Bredemeier M,
    2. Rocha CM,
    3. Barbosa MV,
    4. Pitrez EH
    . One-year clinical and radiological evolution of a patient with refractory Takayasu’s arteritis under treatment with tocilizumab. Clin Exp Rheumatol 2012;1 Suppl 70:S98–100.
    OpenUrl
  15. 15.↵
    1. Unizony S,
    2. Arias-Urdaneta L,
    3. Miloslavsky E,
    4. Arvikar S,
    5. Khosroshahi A,
    6. Keroack B,
    7. et al.
    Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica. Arthritis Care Res 2012;64:1720–9.
    OpenUrl
  16. 16.↵
    1. Salvarani C,
    2. Magnani L,
    3. Catanoso M,
    4. Pipitone N,
    5. Versari A,
    6. Dardani L,
    7. et al.
    Tocilizumab: a novel therapy for patients with large-vessel vasculitis. Rheumatology 2012;51:151–6.
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    1. Molloy ES,
    2. Langford CA,
    3. Clark TM,
    4. Gota CE,
    5. Hoffman GS
    . Anti-tumour necrosis factor therapy in patients with refractory Takayasu arteritis: long-term follow-up. Ann Rheum Dis 2008;67:1567–9.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Kerr GS
    . Takayasu’s arteritis. Rheum Dis Clin North Am 1995;21:1041–58.
    OpenUrlPubMed
  19. 19.↵
    1. Xenitidis T,
    2. Horger M,
    3. Zeh G,
    4. Kanz L,
    5. Henes JC
    . Sustained inflammation of the aortic wall despite tocilizumab treatment in two cases of Takayasu arteritis. Rheumatology 2013;52:1729–31.
    OpenUrlFREE Full Text
  20. 20.↵
    1. Dagna L,
    2. Salvo F,
    3. Tiraboschi M,
    4. Bozzolo EP,
    5. Franchini S,
    6. Doglioni C,
    7. et al.
    Pentraxin-3 as a marker of disease activity in Takayasu arteritis. Ann Intern Med 2011;155:425–33.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 40, Issue 12
1 Dec 2013
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Treatment of Refractory Takayasu Arteritis with Tocilizumab: 7 Italian Patients from a Single Referral Center
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Treatment of Refractory Takayasu Arteritis with Tocilizumab: 7 Italian Patients from a Single Referral Center
Enrico Tombetti, Stefano Franchini, Maurizio Papa, Maria Grazia Sabbadini, Elena Baldissera
The Journal of Rheumatology Dec 2013, 40 (12) 2047-2051; DOI: 10.3899/jrheum.130536

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Treatment of Refractory Takayasu Arteritis with Tocilizumab: 7 Italian Patients from a Single Referral Center
Enrico Tombetti, Stefano Franchini, Maurizio Papa, Maria Grazia Sabbadini, Elena Baldissera
The Journal of Rheumatology Dec 2013, 40 (12) 2047-2051; DOI: 10.3899/jrheum.130536
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • Acknowledgment
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
  • eLetters

Keywords

TAKAYASU ARTERITIS
TOCILIZUMAB
INTERLEUKIN 6
VASCULITIS

Related Articles

Cited By...

More in this TOC Section

  • Sleep Problems in Patients With Psoriatic Arthritis: A Systematic Literature Review and Metaanalysis
  • The Prognostic Potential of End-Stage Knee Osteoarthritis and Its Components to Predict Knee Replacement: Data From the Osteoarthritis Initiative
  • Advances and Controversies in Our Understanding of Guttate and Plaque Psoriasis
Show more Articles

Similar Articles

Keywords

  • Takayasu arteritis
  • tocilizumab
  • INTERLEUKIN 6
  • vasculitis

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2022 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire